Company: OSRH
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076461
Chunk: 39

Company: OSR Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
’s commitment to explore novel avenues
for financing, providing the Company with the ability to more effectively manage capital while maintaining compliance with securities
laws. While the tokenization strategy is still in its early stages, our management views it as a promising long-term initiative that
could significantly enhance the Company’s financial flexibility and increase the attractiveness of the Company to both institutional
and retail investors.

Signing of Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive
Glucose Monitoring Technology

As previously disclosed in the Company’s Current Report on Form
8-K filed on July 25, 2025, we announced in July 2025 the signing of a term sheet with Woori IO Co., Ltd., a leader in noninvasive glucose
monitoring technology based out of South Korea. Under this agreement, OSRH intends to acquire Woori IO, subject to completion of due
diligence and other conditions. This acquisition would further strengthens OSRH’s presence in the burgeoning healthcare and medical
technology sectors, particularly in diabetes management, which is expected to see substantial growth over the next decade.

Woori IO’s proprietary noninvasive continuous glucose monitoring
(CGM) technology is poised to disrupt the current market by providing a pain-free alternative to traditional glucose monitoring methods.
The company’s platform leverages near-infrared spectroscopy (NIRS) technology, which has already demonstrated promising proof-of-concept
results from the studies conducted at the Korea University Hospital (Guro). This acquisition represents a strategic entry into the global
CGM1 market, which is forecast to exceed $47 billion by 20342.

The acquisition, if consummated, is expected to enhance OSRH’s growth
trajectory by providing access to cutting-edge technology in a high-demand area. Management believes that integrating Woori IO’s
noninvasive glucose monitoring solutions with OSRH’s resources will accelerate the commercialization of this technology and open
significant revenue opportunities. The deal structure, as outlined in the term sheet, will involve the issuance of OSRH shares to Woori
IO’s stakeholders upon closing, subject to performance-based milestones (“$10 per share condition”), and will not result
in immediate dilution for existing OSRH shareholders .

Strategic Outlook

Both initiatives reflect OSRH’s ongoing commitment to enhancing
shareholder value through innovative business strategies and investments in high-growth sectors. We will continue to evaluate and pursue
opportunities that align with our strategic vision, particularly in the areas of blockchain and healthcare